NATCLOVIR 500MG INJECTION contains Ganciclovir, which belongs to the group of medicines called Antivirals. It is used to treat cytomegalovirus (CMV) retinitis in people who have acquired immunodeficiency syndrome (AIDS) or in patients undergoing chemotherapy. It is also used to prevent cytomegalovirus (CMV) disease in people who have received a solid organ transplant and are at risk of developing CMV disease.
It is not recommended if you have any pre-existing cytopenia or a history of cytopenic reactions to other drugs, chemicals or irradiation. Inform your doctor if you have kidney, liver or heart diseases. Contact your doctor before receiving this medicine.
NATCLOVIR 500MG INJECTION is not recommended for use by pregnant or breastfeeding women. This medicine is not recommended for use by children. The most common side effects of receiving NATCLOVIR 500MG INJECTION are diarrhea, nausea, headaches and dizziness. Contact your doctor if any of the side effects worsen.
Ganciclovir prevents the multiplication of viruses in human cells. This stops the virus from producing new viruses and clears up your infection.
This medicine will be administered intravenously by your doctor or nurse. Your doctor will administer the correct dose and duration for you depending on your age, body weight and disease condition.
Diarrhoea:
Drink lots of fluids, such as water or fruit juices to keep you hydrated. Do not take any medicine on your own for treating diarrhea. Contact your doctor if the symptom did not improve.
NATCLOVIR 500MG INJECTION is generally not recommended for use in pregnant women. Consult your doctor before receiving it.
It is not known whether NATCLOVIR 500MG INJECTION passes into the breast milk. Consult your doctor before receiving it.
NATCLOVIR 500MG INJECTION should be used with caution in patients with kidney disease or who are receiving hemodialysis. Consult your doctor before receiving it.
NATCLOVIR 500MG INJECTION should be used with caution in patients with liver disease. Consult your doctor before receiving it.
Do not receive NATCLOVIR 500MG INJECTION if you are allergic to Ganciclovir.
NATCLOVIR 500MG INJECTION should be used with caution in patients with heart disease. Consult your doctor before receiving it.
Before receiving, NATCLOVIR 500MG INJECTION inform your doctor if you have:
Use in Pediatrics:
Safety and efficacy are not established in pediatric patients. Consult your doctor before receiving NATCLOVIR 500MG INJECTION.
Use in Geriatrics:
NATCLOVIR 500MG INJECTION should be used with caution in elderly patients. Consult your doctor before receiving it.
A. Drug-Drug interactions:
Inform your doctor if you are receiving any of the following medicine:
Overdosage:
NATCLOVIR 500MG INJECTION will be administered to you only by a doctor or a nurse in a hospital, so it is unlikely to receive an overdose. However, consult your doctor or nurse if you experience any unusual symptoms.
Drug | : | Ganciclovir |
Pharmacological Category | : | Antivirals |
Therapeutic Indication | : | Cytomegalovirus Infection |
Dosage Forms | : | Tablet, Injection, Gel |
Is NATCLOVIR 500MG INJECTION effective?
NATCLOVIR 500MG INJECTION is effective if used according to the dose and duration advised by your doctor. Do not stop taking it even if you see improvement in your condition. If you stop using too early, the symptoms may return or worsen.
How is NATCLOVIR 500MG INJECTION administered?
It should be administered under the supervision of a trained healthcare professional or a doctor only and should not be self-administered. The dose will depend on the condition you are being treated for and will be decided by your doctor. Follow your doctor’s instructions carefully to get the maximum benefit.
Is NATCLOVIR 500MG INJECTION safe?
It is safe if used according to the dose and duration advised by your doctor. Follow your doctor's instructions carefully and let your doctor know if any of the side effects bother you.
1. Alice Tseng, PharmD and Michelle Foisy, PharmD. The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments, May 1996. [Accessed on 3rd December 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327402/
2. Auro Pharma Inc. [Revised on Jan 16, 2018] [Accessed on 3rd December 2022] https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-annex-iii_en.pdf
3. Ganciclovir. CDSCO. [Accessed on 3rd December 2022] https://cdscoonline.gov.in/CDSCO/Drugs
4. Medline plus. [Revised on May 2016] [Accessed on 3rd December 2022] https://medlineplus.gov/druginfo/meds/a605011.html
Written By Dr. Dhivakaran R, BDS
Last updated on 03 Dec 2022 | 12:18 PM(IST)
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.